Posted by Michael Wonder on 14 Apr 2026
Kymera Therapeutics announces US FDA fast track designation for KT-621, a first in class, oral STAT6 degrader for the treatment of moderate to severe asthma
13 April 2026 - Kymera Therapeutics today announced that the US FDA has granted fast track designation to KT-621, its first in class oral STAT6 degrader, for the treatment of moderate to severe eosinophilic asthma.
KT-621 is currently being studied in two global Phase 2b studies, including for the treatment of moderate to severe eosinophilic asthma.
